Chinanews.com, Beijing, March 25 (Liu Wenwen), jointly planned by China National Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Sinopharm Group"), China Traditional Chinese Medicine Holdings Co., Ltd. and the Academy of Chinese Medical Sciences, "Inheriting classic prescriptions, innovating anti-epidemic drugs-chemical "Wet Baidu Granule Product Launch Conference" was held in Beijing on the 25th.
It is reported that Huashi Baidu Granules is another effective drug against the epidemic after the Sinopharm Group has the first and second inactivated vaccines for the new coronavirus in the country.
At the press conference, Sun Da, deputy director of the State Administration of Traditional Chinese Medicine, in his speech affirmed the major strategic achievements made by Chinese medicine in the fight against the new coronavirus, and pointed out that this is the essence of traditional Chinese medicine inheritance and a major practice of maintaining integrity and innovation.
He said that the listing of the three parties represented by Huashibaidu granules is a full recognition of the clinical efficacy of Chinese medicine in the epidemic and the accumulation of scientific data. It is a major and happy event in the development of Chinese medicine.
Huang Luqi, academician of the Chinese Academy of Engineering and president of the Chinese Academy of Chinese Medical Sciences, pointed out that Huashibaidu granules, as a materialized carrier of anti-epidemic work results, are one of the signs of the completion of the anti-epidemic mission delivered by the State Administration of Traditional Chinese Medicine to the Chinese Academy of Chinese Medical Sciences.
He emphasized, "Today's meeting is not only the launch of a drug, but also a way to follow the laws of traditional Chinese medicine and reform the review and approval system of traditional Chinese medicine, which is a milestone."
Yang Longhui, deputy secretary of the Party Committee of the Chinese Academy of Chinese Medical Sciences, reviewed the development process of "Huashibaidu Granules" from four parts: prescription determination, curative effect confirmed, new drug development, and new drug registration.
He said that in the future, new drug research and development will be carried out in accordance with the principle of "Chinese medicine theory, human experience, and clinical trials".
Liu Jingzhen, Secretary of the Party Committee and Chairman of Sinopharm Group, said that in the future, efforts will be made to realize the large-scale mass production of Huashibaidu Granules, which will provide strong support for traditional Chinese medicine to play its unique advantages and role in responding to new and major public health events.
It is reported that the Huashibaidu Granules are the first batch of national Chinese medicine medical teams (the medical team of the Chinese Academy of Chinese Medical Sciences) in the first line of anti-epidemic clinical trials in Wuhan since the outbreak of the new crown pneumonia epidemic. One of the "three medicines and three prescriptions" of the effective prescriptions for pneumonia, it is included in the sixth, seventh and eighth editions of the National Guidelines for the Diagnosis and Treatment of Novel Coronavirus Pneumonia. It is also my country's first batch of ancient classic prescriptions against diseases with completely independent intellectual property rights. One of the chemical compound preparations of traditional Chinese medicine.
It is understood that Huashibaidu Granules will be approved for marketing by the State Food and Drug Administration on March 2, 2021. At present, the undertaker of the industrialization project of Huashibaidu Granules has made relevant preparations for the industrialization of the drug to fully guarantee the supply demand of the market. The next step will be to promote the overseas registration of Huashibaidu Granules. (Finish)